(Albany, US) DelveInsight has launched a new report on Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2030.
DelveInsight’s ‘ Progressive Supranuclear Palsy Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Progressive Supranuclear Palsy in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Some of Progressive Supranuclear Palsy facts:
Request for free Sample Report: https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-market
Scope of Progressive Supranuclear Palsy Report:
Progressive Supranuclear Palsy (PSP) is a rare progressive condition that can cause problems with balance, movement, vision, speech and swallowing.
The condition has been linked to changes in certain genes, but these genetic faults are not inherited and the risk to other family members (including the children or siblings) with PSP, is very low. Although PSP is not fatal, symptoms do continue to worsen and it can not be cured.
Complications that result from worsening symptoms, such as pneumonia (from breathing in food particles while choking during eating) can be life threatening. There are different subtypes of PSP which incudes, PSP with Richardson’s syndrome (PSP-RS), PSP with predominant parkinsonism (PSP-P), PSP with pure akinesia with gait freezing (PSP- PAGF), PSP with corticobasal syndrome (PSP-CBS), PSP with predominant language and speech dysfunction (PSP-PNFA and PSP-AOS), PSP with predominant frontotemporal dysfunction (PSP-FTD), PSP with cerebellar ataxia (PSP-C), and PSP with primary lateral sclerosis (PSP-PLS).
The only proven risk factor for PSP is age. The condition typically affects people around the age of 60, and is virtually unknown in people under the age of 40.
There’s no single test for PSP. Instead, the diagnosis is based on the pattern of the symptoms.
The large number of possible symptoms of PSP also makes it difficult to diagnose correctly and can mean it takes a while to get a definitive diagnosis. Apart from this, PSP is often misdiagnosed as Parkinson disease, Alzheimer disease, corticobasal degeneration and other neurodegenerative disorders.
Some of Progressive Supranuclear Palsy Companies:
Progressive Supranuclear Palsy Drugs Covered:
Table of Contents:
1 Key Insights
2 Executive Summary of Progressive Supranuclear Palsy
3 SWOT Analysis for Progressive Supranuclear Palsy
5 Disease Background and Overview
6 Epidemiology and Patient Population
7 Country Wise-Epidemiology of Progressive Supranuclear Palsy (PSP)
8 Treatment
9 Unmet Needs
10 Emerging drugs
11 Other promising candidates
12 No development reported
13 Discontinued therapies
14 Progressive Supranuclear Palsy (PSP): Seven Major Market Analysis
15 United States
16 EU5 Countries
17 Japan
18 Market Drivers
19 Market Barriers
20 Appendix
21 DelveInsight Capabilities
22 Disclaimer
23 About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/progressive-supranuclear-palsy-market